nodes	percent_of_prediction	percent_of_DWPC	metapath
Nilotinib—MAPK8—artery—abdominal aortic aneurysm	0.0256	0.0749	CbGeAlD
Nilotinib—LYN—blood plasma—abdominal aortic aneurysm	0.0177	0.0519	CbGeAlD
Nilotinib—TEK—artery—abdominal aortic aneurysm	0.0148	0.0432	CbGeAlD
Nilotinib—MAPK14—blood plasma—abdominal aortic aneurysm	0.0122	0.0357	CbGeAlD
Nilotinib—MAPK8—connective tissue—abdominal aortic aneurysm	0.0102	0.0299	CbGeAlD
Nilotinib—UGT1A1—blood plasma—abdominal aortic aneurysm	0.00958	0.028	CbGeAlD
Nilotinib—LYN—connective tissue—abdominal aortic aneurysm	0.00945	0.0276	CbGeAlD
Nilotinib—CSF1R—blood plasma—abdominal aortic aneurysm	0.00884	0.0258	CbGeAlD
Nilotinib—MAPK8—kidney—abdominal aortic aneurysm	0.00872	0.0255	CbGeAlD
Nilotinib—KIT—blood plasma—abdominal aortic aneurysm	0.00803	0.0235	CbGeAlD
Nilotinib—CDC42BPB—spinal cord—abdominal aortic aneurysm	0.00751	0.0219	CbGeAlD
Nilotinib—CA1—blood plasma—abdominal aortic aneurysm	0.00734	0.0215	CbGeAlD
Nilotinib—CA3—connective tissue—abdominal aortic aneurysm	0.00697	0.0204	CbGeAlD
Nilotinib—MAPK8—spinal cord—abdominal aortic aneurysm	0.00679	0.0198	CbGeAlD
Nilotinib—MAPK14—connective tissue—abdominal aortic aneurysm	0.0065	0.019	CbGeAlD
Nilotinib—CA7—kidney—abdominal aortic aneurysm	0.00646	0.0189	CbGeAlD
Nilotinib—EPHB4—connective tissue—abdominal aortic aneurysm	0.00616	0.018	CbGeAlD
Nilotinib—TEK—connective tissue—abdominal aortic aneurysm	0.0059	0.0172	CbGeAlD
Nilotinib—EPHB3—spinal cord—abdominal aortic aneurysm	0.0056	0.0164	CbGeAlD
Nilotinib—MAPK14—kidney—abdominal aortic aneurysm	0.00554	0.0162	CbGeAlD
Nilotinib—PDGFRA—connective tissue—abdominal aortic aneurysm	0.00534	0.0156	CbGeAlD
Nilotinib—EPHB4—kidney—abdominal aortic aneurysm	0.00525	0.0153	CbGeAlD
Nilotinib—HCK—spinal cord—abdominal aortic aneurysm	0.00514	0.015	CbGeAlD
Nilotinib—TEK—kidney—abdominal aortic aneurysm	0.00502	0.0147	CbGeAlD
Nilotinib—CA12—connective tissue—abdominal aortic aneurysm	0.00493	0.0144	CbGeAlD
Nilotinib—CA2—blood plasma—abdominal aortic aneurysm	0.00476	0.0139	CbGeAlD
Nilotinib—CSF1R—connective tissue—abdominal aortic aneurysm	0.00471	0.0138	CbGeAlD
Nilotinib—CYP2C8—blood plasma—abdominal aortic aneurysm	0.00453	0.0132	CbGeAlD
Nilotinib—UGT1A1—kidney—abdominal aortic aneurysm	0.00434	0.0127	CbGeAlD
Nilotinib—MAPK14—spinal cord—abdominal aortic aneurysm	0.00431	0.0126	CbGeAlD
Nilotinib—KIT—connective tissue—abdominal aortic aneurysm	0.00427	0.0125	CbGeAlD
Nilotinib—CA12—kidney—abdominal aortic aneurysm	0.0042	0.0123	CbGeAlD
Nilotinib—CA14—spinal cord—abdominal aortic aneurysm	0.00419	0.0123	CbGeAlD
Nilotinib—PDGFRB—connective tissue—abdominal aortic aneurysm	0.00417	0.0122	CbGeAlD
Nilotinib—EPHB4—spinal cord—abdominal aortic aneurysm	0.00409	0.0119	CbGeAlD
Nilotinib—CYP2B6—blood plasma—abdominal aortic aneurysm	0.00406	0.0119	CbGeAlD
Nilotinib—CYP2C9—blood plasma—abdominal aortic aneurysm	0.00402	0.0118	CbGeAlD
Nilotinib—TEK—spinal cord—abdominal aortic aneurysm	0.00391	0.0114	CbGeAlD
Nilotinib—EPHB6—spinal cord—abdominal aortic aneurysm	0.00374	0.0109	CbGeAlD
Nilotinib—ABL1—connective tissue—abdominal aortic aneurysm	0.00372	0.0109	CbGeAlD
Nilotinib—KIT—kidney—abdominal aortic aneurysm	0.00364	0.0106	CbGeAlD
Nilotinib—PDGFRB—kidney—abdominal aortic aneurysm	0.00355	0.0104	CbGeAlD
Nilotinib—PDGFRA—spinal cord—abdominal aortic aneurysm	0.00354	0.0104	CbGeAlD
Nilotinib—CA1—kidney—abdominal aortic aneurysm	0.00333	0.00972	CbGeAlD
Nilotinib—MAP2K5—spinal cord—abdominal aortic aneurysm	0.0032	0.00934	CbGeAlD
Nilotinib—ABL1—kidney—abdominal aortic aneurysm	0.00317	0.00926	CbGeAlD
Nilotinib—CSF1R—spinal cord—abdominal aortic aneurysm	0.00312	0.00912	CbGeAlD
Nilotinib—CYP3A4—blood plasma—abdominal aortic aneurysm	0.00307	0.00897	CbGeAlD
Nilotinib—CYP2D6—blood plasma—abdominal aortic aneurysm	0.00302	0.00883	CbGeAlD
Nilotinib—KIT—spinal cord—abdominal aortic aneurysm	0.00283	0.00828	CbGeAlD
Nilotinib—PDGFRB—spinal cord—abdominal aortic aneurysm	0.00277	0.00809	CbGeAlD
Nilotinib—CA4—kidney—abdominal aortic aneurysm	0.0026	0.0076	CbGeAlD
Nilotinib—CA1—spinal cord—abdominal aortic aneurysm	0.00259	0.00757	CbGeAlD
Nilotinib—CA2—connective tissue—abdominal aortic aneurysm	0.00253	0.0074	CbGeAlD
Nilotinib—ABL1—spinal cord—abdominal aortic aneurysm	0.00247	0.00721	CbGeAlD
Nilotinib—ABCB1—blood plasma—abdominal aortic aneurysm	0.00217	0.00635	CbGeAlD
Nilotinib—CA2—kidney—abdominal aortic aneurysm	0.00216	0.0063	CbGeAlD
Nilotinib—CYP2C8—kidney—abdominal aortic aneurysm	0.00205	0.006	CbGeAlD
Nilotinib—CA4—spinal cord—abdominal aortic aneurysm	0.00202	0.00592	CbGeAlD
Nilotinib—CYP2B6—kidney—abdominal aortic aneurysm	0.00184	0.00538	CbGeAlD
Nilotinib—CA2—spinal cord—abdominal aortic aneurysm	0.00168	0.00491	CbGeAlD
Nilotinib—ABCG2—spinal cord—abdominal aortic aneurysm	0.00155	0.00454	CbGeAlD
Nilotinib—CYP3A4—kidney—abdominal aortic aneurysm	0.00139	0.00407	CbGeAlD
Nilotinib—CYP2D6—kidney—abdominal aortic aneurysm	0.00137	0.004	CbGeAlD
Nilotinib—ABCB1—kidney—abdominal aortic aneurysm	0.000985	0.00288	CbGeAlD
Nilotinib—ABCB1—spinal cord—abdominal aortic aneurysm	0.000767	0.00224	CbGeAlD
Nilotinib—HCK—Disease—APOE—abdominal aortic aneurysm	0.000196	0.000298	CbGpPWpGaD
Nilotinib—MAPK14—Signaling by NGF—NFKB1—abdominal aortic aneurysm	0.000196	0.000298	CbGpPWpGaD
Nilotinib—FGR—Innate Immune System—NFKB1—abdominal aortic aneurysm	0.000196	0.000298	CbGpPWpGaD
Nilotinib—MAPK14—Hemostasis—NOS2—abdominal aortic aneurysm	0.000195	0.000296	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—LRP1—abdominal aortic aneurysm	0.000194	0.000296	CbGpPWpGaD
Nilotinib—LCK—Disease—AAAS—abdominal aortic aneurysm	0.000193	0.000294	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—LDLR—abdominal aortic aneurysm	0.000192	0.000291	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism of lipids and lipoproteins—LDLR—abdominal aortic aneurysm	0.000191	0.00029	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—LRP1—abdominal aortic aneurysm	0.00019	0.000289	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—LDLR—abdominal aortic aneurysm	0.00019	0.000289	CbGpPWpGaD
Nilotinib—LYN—Axon guidance—MMP9—abdominal aortic aneurysm	0.000189	0.000288	CbGpPWpGaD
Nilotinib—BLK—Adaptive Immune System—NFKB1—abdominal aortic aneurysm	0.000189	0.000287	CbGpPWpGaD
Nilotinib—ABL1—Axon guidance—MMP9—abdominal aortic aneurysm	0.000188	0.000286	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—AAAS—abdominal aortic aneurysm	0.000185	0.000281	CbGpPWpGaD
Nilotinib—HCK—Disease—NOS2—abdominal aortic aneurysm	0.000183	0.000278	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—P2RY12—abdominal aortic aneurysm	0.000182	0.000276	CbGpPWpGaD
Nilotinib—ABCB1—Transmembrane transport of small molecules—AAAS—abdominal aortic aneurysm	0.000181	0.000275	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—AGTR1—abdominal aortic aneurysm	0.000181	0.000275	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—LRP1—abdominal aortic aneurysm	0.00018	0.000274	CbGpPWpGaD
Nilotinib—LYN—Developmental Biology—MMP2—abdominal aortic aneurysm	0.00018	0.000273	CbGpPWpGaD
Nilotinib—MAPK11—Developmental Biology—MMP9—abdominal aortic aneurysm	0.000179	0.000273	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—NCF1—abdominal aortic aneurysm	0.000179	0.000272	CbGpPWpGaD
Nilotinib—ABL1—Developmental Biology—MMP2—abdominal aortic aneurysm	0.000179	0.000272	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—P2RY12—abdominal aortic aneurysm	0.000178	0.000271	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—NCF1—abdominal aortic aneurysm	0.000178	0.00027	CbGpPWpGaD
Nilotinib—MAPK11—Developmental Biology—NFKB1—abdominal aortic aneurysm	0.000177	0.00027	CbGpPWpGaD
Nilotinib—CA4—Metabolism—AGT—abdominal aortic aneurysm	0.000177	0.00027	CbGpPWpGaD
Nilotinib—CA14—Metabolism—PTGS2—abdominal aortic aneurysm	0.000177	0.000269	CbGpPWpGaD
Nilotinib—CA4—Metabolism—APOE—abdominal aortic aneurysm	0.000174	0.000264	CbGpPWpGaD
Nilotinib—LYN—Hemostasis—SERPINE1—abdominal aortic aneurysm	0.000173	0.000263	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—LDLR—abdominal aortic aneurysm	0.000173	0.000263	CbGpPWpGaD
Nilotinib—CA6—Metabolism—PTGS2—abdominal aortic aneurysm	0.000173	0.000262	CbGpPWpGaD
Nilotinib—LCK—Cytokine Signaling in Immune system—NFKB1—abdominal aortic aneurysm	0.000172	0.000262	CbGpPWpGaD
Nilotinib—ABL1—Hemostasis—SERPINE1—abdominal aortic aneurysm	0.000172	0.000262	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—AGTR1—abdominal aortic aneurysm	0.000172	0.000261	CbGpPWpGaD
Nilotinib—LCK—Immune System—NCF1—abdominal aortic aneurysm	0.000171	0.00026	CbGpPWpGaD
Nilotinib—MAPK14—Developmental Biology—MMP2—abdominal aortic aneurysm	0.00017	0.000259	CbGpPWpGaD
Nilotinib—CA2—Metabolism—AGT—abdominal aortic aneurysm	0.00017	0.000258	CbGpPWpGaD
Nilotinib—LCK—Signaling by NGF—NFKB1—abdominal aortic aneurysm	0.00017	0.000258	CbGpPWpGaD
Nilotinib—LCK—Disease—LDLR—abdominal aortic aneurysm	0.000169	0.000257	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—P2RY12—abdominal aortic aneurysm	0.000169	0.000257	CbGpPWpGaD
Nilotinib—LCK—Hemostasis—NOS2—abdominal aortic aneurysm	0.000168	0.000256	CbGpPWpGaD
Nilotinib—CA2—Metabolism—APOE—abdominal aortic aneurysm	0.000167	0.000253	CbGpPWpGaD
Nilotinib—MAPK14—Hemostasis—SERPINE1—abdominal aortic aneurysm	0.000164	0.000249	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—LDLR—abdominal aortic aneurysm	0.000164	0.000249	CbGpPWpGaD
Nilotinib—CA1—Metabolism—AGT—abdominal aortic aneurysm	0.000163	0.000248	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—NCF1—abdominal aortic aneurysm	0.000162	0.000246	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—LDLR—abdominal aortic aneurysm	0.000161	0.000245	CbGpPWpGaD
Nilotinib—CA7—Metabolism—PTGS2—abdominal aortic aneurysm	0.000161	0.000245	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—MMP3—abdominal aortic aneurysm	0.000161	0.000245	CbGpPWpGaD
Nilotinib—CA1—Metabolism—APOE—abdominal aortic aneurysm	0.00016	0.000243	CbGpPWpGaD
Nilotinib—LCK—Disease—NCF1—abdominal aortic aneurysm	0.000158	0.00024	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—AAAS—abdominal aortic aneurysm	0.000157	0.000239	CbGpPWpGaD
Nilotinib—MAPK11—Innate Immune System—NFKB1—abdominal aortic aneurysm	0.000157	0.000238	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—LRP1—abdominal aortic aneurysm	0.000156	0.000237	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism of lipids and lipoproteins—LDLR—abdominal aortic aneurysm	0.000155	0.000236	CbGpPWpGaD
Nilotinib—HCK—Disease—SERPINE1—abdominal aortic aneurysm	0.000154	0.000234	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—MMP3—abdominal aortic aneurysm	0.000153	0.000233	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—NCF1—abdominal aortic aneurysm	0.000153	0.000233	CbGpPWpGaD
Nilotinib—CA12—Metabolism—PTGS2—abdominal aortic aneurysm	0.000149	0.000227	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—LDLR—abdominal aortic aneurysm	0.000147	0.000224	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—P2RY12—abdominal aortic aneurysm	0.000146	0.000222	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—LDLR—abdominal aortic aneurysm	0.000144	0.000219	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—AGTR1—abdominal aortic aneurysm	0.000144	0.000219	CbGpPWpGaD
Nilotinib—CA9—Metabolism—AGT—abdominal aortic aneurysm	0.000143	0.000218	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—AGTR1—abdominal aortic aneurysm	0.000143	0.000217	CbGpPWpGaD
Nilotinib—LCK—Hemostasis—SERPINE1—abdominal aortic aneurysm	0.000142	0.000215	CbGpPWpGaD
Nilotinib—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—abdominal aortic aneurysm	0.000141	0.000215	CbGpPWpGaD
Nilotinib—KIT—Innate Immune System—NFKB1—abdominal aortic aneurysm	0.000141	0.000215	CbGpPWpGaD
Nilotinib—BRAF—Disease—APOE—abdominal aortic aneurysm	0.00014	0.000213	CbGpPWpGaD
Nilotinib—CA9—Metabolism—APOE—abdominal aortic aneurysm	0.00014	0.000213	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—NCF1—abdominal aortic aneurysm	0.000138	0.00021	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—LDLR—abdominal aortic aneurysm	0.000137	0.000208	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—LDLR—abdominal aortic aneurysm	0.000137	0.000208	CbGpPWpGaD
Nilotinib—KIT—Adaptive Immune System—NFKB1—abdominal aortic aneurysm	0.000136	0.000206	CbGpPWpGaD
Nilotinib—LYN—Developmental Biology—MMP9—abdominal aortic aneurysm	0.000135	0.000205	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—NCF1—abdominal aortic aneurysm	0.000135	0.000205	CbGpPWpGaD
Nilotinib—HCK—Disease—PTGS2—abdominal aortic aneurysm	0.000135	0.000204	CbGpPWpGaD
Nilotinib—ABL1—Developmental Biology—MMP9—abdominal aortic aneurysm	0.000134	0.000204	CbGpPWpGaD
Nilotinib—PDGFRA—Innate Immune System—NFKB1—abdominal aortic aneurysm	0.000134	0.000203	CbGpPWpGaD
Nilotinib—LYN—Developmental Biology—NFKB1—abdominal aortic aneurysm	0.000134	0.000203	CbGpPWpGaD
Nilotinib—ABL1—Developmental Biology—NFKB1—abdominal aortic aneurysm	0.000133	0.000202	CbGpPWpGaD
Nilotinib—BRAF—Disease—NOS2—abdominal aortic aneurysm	0.000131	0.000199	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—AGTR1—abdominal aortic aneurysm	0.00013	0.000197	CbGpPWpGaD
Nilotinib—PDGFRA—Adaptive Immune System—NFKB1—abdominal aortic aneurysm	0.000128	0.000195	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—MMP3—abdominal aortic aneurysm	0.000128	0.000195	CbGpPWpGaD
Nilotinib—MAPK14—Developmental Biology—MMP9—abdominal aortic aneurysm	0.000128	0.000195	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—NCF1—abdominal aortic aneurysm	0.000128	0.000194	CbGpPWpGaD
Nilotinib—KIT—Disease—APOE—abdominal aortic aneurysm	0.000128	0.000194	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—AGT—abdominal aortic aneurysm	0.000127	0.000193	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—MMP3—abdominal aortic aneurysm	0.000127	0.000193	CbGpPWpGaD
Nilotinib—MAPK14—Developmental Biology—NFKB1—abdominal aortic aneurysm	0.000127	0.000193	CbGpPWpGaD
Nilotinib—HCK—Immune System—NFKB1—abdominal aortic aneurysm	0.000126	0.000192	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—APOE—abdominal aortic aneurysm	0.000125	0.000189	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—AGTR1—abdominal aortic aneurysm	0.000123	0.000187	CbGpPWpGaD
Nilotinib—ABCB1—Integrated Pancreatic Cancer Pathway—NFKB1—abdominal aortic aneurysm	0.000123	0.000186	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—APOE—abdominal aortic aneurysm	0.000121	0.000184	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—AGT—abdominal aortic aneurysm	0.000121	0.000184	CbGpPWpGaD
Nilotinib—PDGFRB—Innate Immune System—NFKB1—abdominal aortic aneurysm	0.000121	0.000183	CbGpPWpGaD
Nilotinib—MAPK11—Gene Expression—SERPINE1—abdominal aortic aneurysm	0.00012	0.000182	CbGpPWpGaD
Nilotinib—KIT—Disease—NOS2—abdominal aortic aneurysm	0.000119	0.000181	CbGpPWpGaD
Nilotinib—CA4—Metabolism—PTGS2—abdominal aortic aneurysm	0.000119	0.000181	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—APOE—abdominal aortic aneurysm	0.000118	0.00018	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—LDLR—abdominal aortic aneurysm	0.000118	0.00018	CbGpPWpGaD
Nilotinib—LYN—Innate Immune System—NFKB1—abdominal aortic aneurysm	0.000118	0.000179	CbGpPWpGaD
Nilotinib—ABL1—Innate Immune System—NFKB1—abdominal aortic aneurysm	0.000117	0.000179	CbGpPWpGaD
Nilotinib—PDGFRB—Adaptive Immune System—NFKB1—abdominal aortic aneurysm	0.000116	0.000176	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—MMP3—abdominal aortic aneurysm	0.000116	0.000176	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—AAAS—abdominal aortic aneurysm	0.000115	0.000175	CbGpPWpGaD
Nilotinib—BLK—Immune System—NFKB1—abdominal aortic aneurysm	0.000115	0.000174	CbGpPWpGaD
Nilotinib—MAPK8—Immune System—NFKB1—abdominal aortic aneurysm	0.000115	0.000174	CbGpPWpGaD
Nilotinib—FGR—Immune System—NFKB1—abdominal aortic aneurysm	0.000114	0.000174	CbGpPWpGaD
Nilotinib—CA2—Metabolism—PTGS2—abdominal aortic aneurysm	0.000114	0.000174	CbGpPWpGaD
Nilotinib—LYN—Adaptive Immune System—NFKB1—abdominal aortic aneurysm	0.000113	0.000172	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—NOS2—abdominal aortic aneurysm	0.000113	0.000171	CbGpPWpGaD
Nilotinib—MAPK14—Innate Immune System—NFKB1—abdominal aortic aneurysm	0.000112	0.00017	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—AGTR1—abdominal aortic aneurysm	0.000111	0.000168	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—NCF1—abdominal aortic aneurysm	0.000111	0.000168	CbGpPWpGaD
Nilotinib—BRAF—Disease—SERPINE1—abdominal aortic aneurysm	0.00011	0.000167	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—MMP3—abdominal aortic aneurysm	0.00011	0.000166	CbGpPWpGaD
Nilotinib—CA1—Metabolism—PTGS2—abdominal aortic aneurysm	0.000109	0.000166	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—APOE—abdominal aortic aneurysm	0.000109	0.000166	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—AGTR1—abdominal aortic aneurysm	0.000108	0.000165	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—CCL2—abdominal aortic aneurysm	0.000105	0.000159	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—AGTR1—abdominal aortic aneurysm	0.000103	0.000156	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—NOS2—abdominal aortic aneurysm	0.000102	0.000154	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—AGT—abdominal aortic aneurysm	0.000101	0.000154	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism of lipids and lipoproteins—AGT—abdominal aortic aneurysm	0.000101	0.000153	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—LDLR—abdominal aortic aneurysm	0.0001	0.000153	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—AGT—abdominal aortic aneurysm	0.0001	0.000153	CbGpPWpGaD
Nilotinib—KIT—Disease—SERPINE1—abdominal aortic aneurysm	0.0001	0.000152	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—CCL2—abdominal aortic aneurysm	9.96e-05	0.000151	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—APOE—abdominal aortic aneurysm	9.92e-05	0.000151	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism of lipids and lipoproteins—APOE—abdominal aortic aneurysm	9.89e-05	0.00015	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—MMP3—abdominal aortic aneurysm	9.87e-05	0.00015	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—APOE—abdominal aortic aneurysm	9.83e-05	0.000149	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—SERPINE1—abdominal aortic aneurysm	9.77e-05	0.000149	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—AAAS—abdominal aortic aneurysm	9.74e-05	0.000148	CbGpPWpGaD
Nilotinib—LCK—Innate Immune System—NFKB1—abdominal aortic aneurysm	9.67e-05	0.000147	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—MMP3—abdominal aortic aneurysm	9.66e-05	0.000147	CbGpPWpGaD
Nilotinib—BRAF—Disease—PTGS2—abdominal aortic aneurysm	9.62e-05	0.000146	CbGpPWpGaD
Nilotinib—CA9—Metabolism—PTGS2—abdominal aortic aneurysm	9.62e-05	0.000146	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—SERPINE1—abdominal aortic aneurysm	9.49e-05	0.000144	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—SERPINE1—abdominal aortic aneurysm	9.29e-05	0.000141	CbGpPWpGaD
Nilotinib—LCK—Adaptive Immune System—NFKB1—abdominal aortic aneurysm	9.29e-05	0.000141	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—MMP3—abdominal aortic aneurysm	9.16e-05	0.000139	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—AGT—abdominal aortic aneurysm	9.13e-05	0.000139	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—NFKB1—abdominal aortic aneurysm	9.13e-05	0.000139	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—APOE—abdominal aortic aneurysm	8.95e-05	0.000136	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—AGTR1—abdominal aortic aneurysm	8.88e-05	0.000135	CbGpPWpGaD
Nilotinib—KIT—Disease—PTGS2—abdominal aortic aneurysm	8.76e-05	0.000133	CbGpPWpGaD
Nilotinib—LCK—Disease—APOE—abdominal aortic aneurysm	8.75e-05	0.000133	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—AGT—abdominal aortic aneurysm	8.65e-05	0.000131	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—SERPINE1—abdominal aortic aneurysm	8.55e-05	0.00013	CbGpPWpGaD
Nilotinib—MAPK14—Gene Expression—SERPINE1—abdominal aortic aneurysm	8.55e-05	0.00013	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—AGT—abdominal aortic aneurysm	8.54e-05	0.00013	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—LDLR—abdominal aortic aneurysm	8.5e-05	0.000129	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—AAAS—abdominal aortic aneurysm	8.49e-05	0.000129	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—APOE—abdominal aortic aneurysm	8.47e-05	0.000129	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—APOE—abdominal aortic aneurysm	8.36e-05	0.000127	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—CCL2—abdominal aortic aneurysm	8.34e-05	0.000127	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—PTGS2—abdominal aortic aneurysm	8.29e-05	0.000126	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—CCL2—abdominal aortic aneurysm	8.26e-05	0.000126	CbGpPWpGaD
Nilotinib—KIT—Immune System—NFKB1—abdominal aortic aneurysm	8.23e-05	0.000125	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism of lipids and lipoproteins—AGT—abdominal aortic aneurysm	8.21e-05	0.000125	CbGpPWpGaD
Nilotinib—LCK—Disease—NOS2—abdominal aortic aneurysm	8.15e-05	0.000124	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism of lipids and lipoproteins—APOE—abdominal aortic aneurysm	8.05e-05	0.000122	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—AAAS—abdominal aortic aneurysm	8e-05	0.000122	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—AAAS—abdominal aortic aneurysm	7.93e-05	0.00012	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—MMP3—abdominal aortic aneurysm	7.92e-05	0.00012	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—NFKB1—abdominal aortic aneurysm	7.79e-05	0.000118	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—AGT—abdominal aortic aneurysm	7.79e-05	0.000118	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—SERPINE1—abdominal aortic aneurysm	7.79e-05	0.000118	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—SERPINE1—abdominal aortic aneurysm	7.72e-05	0.000117	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—APOE—abdominal aortic aneurysm	7.63e-05	0.000116	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—AGT—abdominal aortic aneurysm	7.63e-05	0.000116	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—CCL2—abdominal aortic aneurysm	7.52e-05	0.000114	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—MMP9—abdominal aortic aneurysm	7.49e-05	0.000114	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—APOE—abdominal aortic aneurysm	7.47e-05	0.000114	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—PTGS2—abdominal aortic aneurysm	7.47e-05	0.000114	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—LDLR—abdominal aortic aneurysm	7.41e-05	0.000113	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—NFKB1—abdominal aortic aneurysm	7.41e-05	0.000113	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—AGT—abdominal aortic aneurysm	7.24e-05	0.00011	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—AGT—abdominal aortic aneurysm	7.23e-05	0.00011	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—CCL2—abdominal aortic aneurysm	7.12e-05	0.000108	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—MMP9—abdominal aortic aneurysm	7.12e-05	0.000108	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—APOE—abdominal aortic aneurysm	7.1e-05	0.000108	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—APOE—abdominal aortic aneurysm	7.08e-05	0.000108	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—NFKB1—abdominal aortic aneurysm	7.04e-05	0.000107	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—SERPINE1—abdominal aortic aneurysm	7.02e-05	0.000107	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—NFKB1—abdominal aortic aneurysm	7.02e-05	0.000107	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—LDLR—abdominal aortic aneurysm	6.98e-05	0.000106	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—LDLR—abdominal aortic aneurysm	6.92e-05	0.000105	CbGpPWpGaD
Nilotinib—LYN—Immune System—NFKB1—abdominal aortic aneurysm	6.87e-05	0.000104	CbGpPWpGaD
Nilotinib—LCK—Disease—SERPINE1—abdominal aortic aneurysm	6.86e-05	0.000104	CbGpPWpGaD
Nilotinib—ABL1—Immune System—NFKB1—abdominal aortic aneurysm	6.84e-05	0.000104	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—abdominal aortic aneurysm	6.78e-05	0.000103	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—SERPINE1—abdominal aortic aneurysm	6.65e-05	0.000101	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—NFKB1—abdominal aortic aneurysm	6.52e-05	9.9e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—CCL2—abdominal aortic aneurysm	6.41e-05	9.75e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—CCL2—abdominal aortic aneurysm	6.28e-05	9.55e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—AGT—abdominal aortic aneurysm	6.25e-05	9.5e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—APOE—abdominal aortic aneurysm	6.12e-05	9.31e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—PTGS2—abdominal aortic aneurysm	5.99e-05	9.11e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—SERPINE1—abdominal aortic aneurysm	5.99e-05	9.1e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—MMP9—abdominal aortic aneurysm	5.97e-05	9.07e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—CCL2—abdominal aortic aneurysm	5.95e-05	9.05e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—MMP9—abdominal aortic aneurysm	5.91e-05	8.98e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—NFKB1—abdominal aortic aneurysm	5.9e-05	8.97e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—SERPINE1—abdominal aortic aneurysm	5.86e-05	8.91e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—NFKB1—abdominal aortic aneurysm	5.85e-05	8.89e-05	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—PTGS2—abdominal aortic aneurysm	5.73e-05	8.71e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—NFKB1—abdominal aortic aneurysm	5.63e-05	8.56e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—SERPINE1—abdominal aortic aneurysm	5.56e-05	8.45e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—abdominal aortic aneurysm	5.51e-05	8.38e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—MMP9—abdominal aortic aneurysm	5.38e-05	8.18e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—NFKB1—abdominal aortic aneurysm	5.32e-05	8.09e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—AGT—abdominal aortic aneurysm	5.31e-05	8.07e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—AAAS—abdominal aortic aneurysm	5.23e-05	7.95e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—APOE—abdominal aortic aneurysm	5.2e-05	7.91e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—CCL2—abdominal aortic aneurysm	5.15e-05	7.83e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—MMP9—abdominal aortic aneurysm	5.09e-05	7.74e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—NFKB1—abdominal aortic aneurysm	5.04e-05	7.66e-05	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—PTGS2—abdominal aortic aneurysm	4.86e-05	7.39e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—SERPINE1—abdominal aortic aneurysm	4.81e-05	7.31e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—MMP9—abdominal aortic aneurysm	4.59e-05	6.97e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—LDLR—abdominal aortic aneurysm	4.56e-05	6.94e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—NFKB1—abdominal aortic aneurysm	4.54e-05	6.9e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—AGT—abdominal aortic aneurysm	4.49e-05	6.83e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—MMP9—abdominal aortic aneurysm	4.49e-05	6.83e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—NFKB1—abdominal aortic aneurysm	4.44e-05	6.75e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—APOE—abdominal aortic aneurysm	4.4e-05	6.69e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—MMP9—abdominal aortic aneurysm	4.26e-05	6.47e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—NFKB1—abdominal aortic aneurysm	4.21e-05	6.4e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—AGT—abdominal aortic aneurysm	3.92e-05	5.95e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—APOE—abdominal aortic aneurysm	3.84e-05	5.83e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—AGT—abdominal aortic aneurysm	3.69e-05	5.61e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—MMP9—abdominal aortic aneurysm	3.68e-05	5.6e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—AGT—abdominal aortic aneurysm	3.66e-05	5.56e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—NFKB1—abdominal aortic aneurysm	3.64e-05	5.54e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—APOE—abdominal aortic aneurysm	3.62e-05	5.5e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—APOE—abdominal aortic aneurysm	3.58e-05	5.45e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—PTGS2—abdominal aortic aneurysm	3.56e-05	5.42e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—PTGS2—abdominal aortic aneurysm	3.02e-05	4.59e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—PTGS2—abdominal aortic aneurysm	2.63e-05	4e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—PTGS2—abdominal aortic aneurysm	2.48e-05	3.77e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—PTGS2—abdominal aortic aneurysm	2.46e-05	3.73e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—AGT—abdominal aortic aneurysm	2.41e-05	3.67e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—APOE—abdominal aortic aneurysm	2.36e-05	3.59e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—PTGS2—abdominal aortic aneurysm	1.62e-05	2.46e-05	CbGpPWpGaD
